89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma
Clinical trial NCT06537596 · RECRUITING
Trial details
- NCT number
- NCT06537596
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-31
- Primary completion
- 2027-10-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.